MHRAsafety guidance72% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (copd) as AstraZeneca.
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Respiratory · COPD
- Sub-indication
- COPD
Related signal: AstraZeneca initiates Phase 3 extension study for Tozorakimab in COPD patients